U.S. Markets open in 8 hrs 58 mins

Evolent Health (EVH) Looks Good: Stock Adds 5.5% in Session

Zacks Equity Research
Evolent Health (EVH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Evolent Health, Inc. EVH was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 14.8% in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Evolent Health currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.  

Evolent Health, Inc Price

Evolent Health, Inc Price | Evolent Health, Inc Quote

A better-ranked stock in the Internet – Software industry is Attunity Ltd. ATTU, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EVH going up? Or down? Predict to see what others think:Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Evolent Health, Inc (EVH) : Free Stock Analysis Report
 
Attunity Ltd. (ATTU) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research